DF Dent & Co. Inc. grew its holdings in Illumina (NASDAQ:ILMN) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 501,206 shares of the life sciences company’s stock after purchasing an additional 14,676 shares during the quarter. Illumina comprises approximately 2.8% of DF Dent & Co. Inc.’s portfolio, making the stock its 11th largest holding. DF Dent & Co. Inc. owned approximately 0.34% of Illumina worth $109,508,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. MetLife Investment Advisors LLC purchased a new stake in shares of Illumina during the 4th quarter valued at approximately $9,870,000. Gotham Asset Management LLC purchased a new stake in shares of Illumina during the 4th quarter valued at approximately $439,000. Vident Investment Advisory LLC raised its position in shares of Illumina by 50.2% during the 4th quarter. Vident Investment Advisory LLC now owns 4,718 shares of the life sciences company’s stock valued at $1,031,000 after buying an additional 1,577 shares during the period. Zeke Capital Advisors LLC raised its position in shares of Illumina by 52.9% during the 4th quarter. Zeke Capital Advisors LLC now owns 3,935 shares of the life sciences company’s stock valued at $860,000 after buying an additional 1,361 shares during the period. Finally, Meadow Creek Investment Management LLC raised its position in shares of Illumina by 17.9% during the 4th quarter. Meadow Creek Investment Management LLC now owns 4,620 shares of the life sciences company’s stock valued at $1,009,000 after buying an additional 700 shares during the period. 91.40% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently commented on the stock. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, March 10th. Deutsche Bank set a $275.00 price target on shares of Illumina and gave the company a “buy” rating in a research report on Tuesday, January 16th. Cowen lifted their price target on shares of Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a research report on Monday, January 22nd. Leerink Swann lifted their price target on shares of Illumina from $250.00 to $276.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Finally, Morgan Stanley lifted their price target on shares of Illumina from $145.00 to $157.00 and gave the company an “underweight” rating in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $241.39.
Shares of Illumina stock opened at $253.91 on Monday. The stock has a market capitalization of $37,324.77, a P/E ratio of 63.32, a price-to-earnings-growth ratio of 3.36 and a beta of 0.93. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.99 and a quick ratio of 3.55. Illumina has a 12-month low of $158.64 and a 12-month high of $256.64.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.22. The company had revenue of $778.00 million for the quarter, compared to analyst estimates of $752.04 million. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The firm’s quarterly revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.85 earnings per share. equities research analysts expect that Illumina will post 4.59 EPS for the current year.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $215.48, for a total value of $4,309,600.00. Following the completion of the transaction, the director now owns 480,476 shares in the company, valued at $103,532,968.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Frances Arnold sold 250 shares of the business’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $252.26, for a total transaction of $63,065.00. Following the completion of the transaction, the director now owns 10,189 shares of the company’s stock, valued at approximately $2,570,277.14. The disclosure for this sale can be found here. In the last three months, insiders sold 73,137 shares of company stock worth $16,573,090. 0.89% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This story was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/19/df-dent-co-inc-grows-holdings-in-illumina-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.